Lotus Pharmaceutical Co., Ltd.

TWSE:1795 Stock Report

Market Cap: NT$69.1b

Lotus Pharmaceutical Management

Management criteria checks 1/4

Lotus Pharmaceutical's CEO is Petar Vazharov, appointed in Jan 2018, has a tenure of 6.92 years. directly owns 0.38% of the company’s shares, worth NT$260.50M. The average tenure of the management team and the board of directors is 3.3 years and 1.5 years respectively.

Key information

Petar Vazharov

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.9yrs
CEO ownership0.4%
Management average tenure3.3yrs
Board average tenure1.5yrs

Recent management updates

Recent updates

Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Dec 04
Market Cool On Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Earnings

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

CEO Compensation Analysis

How has Petar Vazharov's remuneration changed compared to Lotus Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

NT$4b

Jun 30 2024n/an/a

NT$4b

Mar 31 2024n/an/a

NT$4b

Dec 31 2023n/an/a

NT$4b

Sep 30 2023n/an/a

NT$4b

Jun 30 2023n/an/a

NT$5b

Mar 31 2023n/an/a

NT$4b

Dec 31 2022n/an/a

NT$3b

Sep 30 2022n/an/a

NT$3b

Jun 30 2022n/an/a

NT$1b

Mar 31 2022n/an/a

NT$1b

Dec 31 2021NT$35mNT$28m

NT$1b

Sep 30 2021n/an/a

NT$1b

Jun 30 2021n/an/a

NT$1b

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$18mNT$14m

NT$1b

Sep 30 2020n/an/a

NT$848m

Jun 30 2020n/an/a

NT$769m

Mar 31 2020n/an/a

NT$519m

Dec 31 2019NT$13mNT$7m

NT$663m

Compensation vs Market: Insufficient data to establish whether Petar's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Petar's compensation has increased by more than 20% in the past year.

CEO

Petar Vazharov

6.9yrs

Tenure

NT$34,721,000

Compensation

Mr. Petar Antonov Vazharov serves as a Director at Alvogen Korea Co. Ltd. Since March 31, 2021. He is an Executive Vice President of the Asia Pacific Region of Alvogen Group.He is General Manager of Alvog...

Leadership Team

NamePositionTenureCompensationOwnership
Petar Vazharov
CEO & Director6.9yrsNT$34.72m0.38%
NT$ 260.5m
Eeling Chan
Chief Financial Officer8.1yrsNT$5.19m0.010%
NT$ 6.9m
Vamsi Kosaraju
Chief Operations Officerless than a yearno datano data
Gwen Hsieh
Chief Information Officer3.3yrsno data0.0084%
NT$ 5.8m
Yu-Ying Yang
Associate Director of Co-Operate Communicationno datano datano data
Boon Tan
Deputy General Managerno datano data0.0077%
NT$ 5.3m
Edin Buljubasic
Vice Presidentno datano data0.057%
NT$ 39.1m
Yingming Yue
Vice Presidentno datano data0.011%
NT$ 7.8m
Valerie Lau
Chief Commercial Officer-APACless than a yearno datano data
Manish Chawla
Vice President of Research and Developmentno datano data0.019%
NT$ 13.0m

3.3yrs

Average Tenure

Experienced Management: 1795's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Petar Vazharov
CEO & Director10.3yrsNT$34.72m0.38%
NT$ 260.5m
Vilhelm Wessman
Chairman9.7yrsNT$959.00kno data
Karl Alexius Tiger Karlsson
Independent Director1.5yrsno datano data
Oranee Tangphao-Daniels
Director2.5yrsno datano data
Arni Hardarson
Representative Directorless than a yearNT$959.00kno data
Yves Hermes
Director2.5yrsno datano data
Chuan-Fen Wang
Independent Dierctor1.5yrsno datano data
Nat Ativitavas
Representative Director1.3yrsno datano data
Krisana Winitthumkul
Director2.1yrsno datano data
Ivy Yang
Independent Directorless than a yearno datano data
Thariswan Tiensawat
Representative Directorless than a yearno datano data

1.5yrs

Average Tenure

55yo

Average Age

Experienced Board: 1795's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 15:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lotus Pharmaceutical Co., Ltd. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCapital Securities Corporation
Jianzheng WuCapital Securities Corporation
Hsuan ChenKGI Securities Co. Ltd.